Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma

Thoracic Cancer

Mao-Bin Meng¹  Chao Jiang¹  Li-Jun Tian¹  Chun-Lei Liu¹  Hong-Qing Zhuang¹  Zhong-Jie Chen¹  Yong-Chun Song¹  Jun Wang¹  Qing-Song Pang¹  Lu-Jun Zhao¹  Zhi-Yong Yuan² 

[1] Department of Radiation Oncology, Tianjin Medical University Cancer Hospital & Institute, Tianjin, China;Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Hospital & Institute, Tianjin, China

关键词: Esophageal squamous cell carcinoma;    late course accelerated hyperfractionation radiotherapy;    meta‐analysis;    randomized controlled trial;   

DOI  :  10.1111/j.1759-7714.2012.00166.x

来源: Wiley

【 摘 要 】

Abstract

Background

Late course accelerated hyperfractionation radiotherapy (LCAHR) is used as a standard treatment option for locally advanced esophageal squamous cell carcinoma (LAESCC) in China, but concerns remain regarding its efficacy and safety. The purpose of this paper was to evaluate the efficacy and safety of LCAHR. The comparisons examined were as follows: LCAHR versus conventional fractionation radiotherapy (CFR) and LCAHR plus chemotherapy (CT) versus LCAHR alone.

Methods

We searched the Cochrane Library, MEDLINE, EMBASE, CENTRAL, CBMdisc, and CNKI, as well as employing manual searches. The primary end points were survival and local control. The second end point was toxicities.

Results

Based on search criteria, we found 29 trials involving 3187 patients. Our results showed that LCAHR, compared with CFR, improved the survival and local control, and was, thus, more therapeutically beneficial. Further analysis revealed that LCAHR plus CT proved to be better for patients' survival and local control compared to LCAHR alone. Acute toxicities were increased rather than late toxicities.

Conclusions

There was a significant survival and local control benefit of LCAHR over CFR, as well as LCAHR plus CT over LCAHR alone. Considering the strength of the evidence, the results of this study indicate that this regimen would be a new promising modality worth further investigation.

【 授权许可】

Unknown   
© 2012 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd